CurrentPremera BluecrossPolicy N/A

1.01.508 Negative Pressure Wound Therapy (NPWT) Devices in Adults

Defines medical necessity, continuation, investigational status, documentation, coding, contraindications, and evidence for powered and single-use NPWT devices for adults aged 19 and older in the outpatient setting.

Policy Summary

PayerPremera Bluecross

Policy1.01.508 Negative Pressure Wound Therapy (NPWT) Devices in Adults

Policy CodePolicy N/A

Change TypeNew policy; annual review; code clarifications

Effective DateDec 4, 2025

Next Review DateNov 14, 2026

Key ActionSubmit medical records documenting that initiation criteria are met to justify a 2-week therapeutic trial and initial 30-day authorization.

SourceLink

POLICY UPDATE CHANGES

New policy 1.01.508 Negative Pressure Wound Therapy (NPWT) Devices in Adults approved August 12, 2025, effective for dates of service on or after December 4, 2025.

Annual Review on 04/01/26 updated literature review through November 14, 2025; references added; policy statements unchanged.

Codes added to policy section for ease of interpretation and application; HCPCS codes A7000 and A7001 removed.

01/25/12 HCPCS code A9272 added to policy (historical entry).

06/13/11 policy updated adding term 'powered' to existing policy statements and adding that nonpowered NPWT systems are investigational (historical).

2 weeksMinimum therapeutic trial

30 daysInitial approval period

150-200 mL/day

High-volume drainage threshold

≥90 daysChronic pressure ulcer duration

≥30 daysNonhealing wound duration with comorbidity

Coverage Summary & Scope

Scope: This policy defines medical necessity, continuation, investigational status, documentation, coding, contraindications, and evidence for powered and single-use NPWT devices for adults aged 19 and older in the outpatient setting. The policy focuses on outpatient adult use of NPWT and distinguishes powered systems (covered when criteria are met) from single-use systems (investigational).

Overview: Negative Pressure Wound Therapy (NPWT) is addressed only for adult outpatients; devices and indications are specified with initiation and continuation criteria, required documentation, and coding guidance. Policy status: CURRENT. New policy 1.01.508 Negative Pressure Wound Therapy (NPWT) Devices in Adults approved August 12, 2025, and effective for dates of service on or after December 4, 2025, following a 90-day provider notification; annual review approved March 9, 2026, with literature updated through November 14, 2025 and policy statements unchanged.

Key thresholds and policy quick facts

Minimum therapeutic trial2 weeks

Initial approval period30 days

High-volume drainage threshold150-200 mL/day

Chronic pressure ulcer duration≥90 days

Nonhealing wound duration≥30 days

Monitoring frequencyNot less than every 14 days

Policy effective date2025-12-04

Last annual review date2026-03-09

Key HCPCS codeA9272

Initiation of Powered NPWT (Medical Necessity)

An initial therapeutic trial of not less than 2 weeks using a powered negative pressure wound therapy (NPWT) system, as part of a comprehensive wound care program that includes controlling factors (e.g., diabetes, nutrition, relief of pressure), may be considered medically necessary in adults for ANY of the following indications:

ANY of the following

Chronic stage III/IV pressure ulcers
- Chronic (greater than 90 days) stage III or IV pressure ulcer that has failed to heal despite optimal wound care
- High-volume drainage that interferes with healing and/or when standard dressings cannot be maintained due to anatomic factors
  High-volume drainage is defined as exudate exceeding 150 - 200 mL/day that overwhelms NPWT dressings, breaks seal integrity, and hinders healing.
Nonhealing wounds in individuals with underlying conditions

Continuation of Powered NPWT (Medical Necessity & Not Medically Necessary)

Single-Use NPWT Systems — Investigational / Not Covered

General Not Medically Necessary: Therapeutic trials of powered NPWT systems for the treatment of other acute or chronic wounds that do not meet the specified initiation criteria are considered not medically necessary.

Authorization Periods and Re-authorization

Initial approval length

When criteria for initial powered NPWT are met:

Initial approval length: Initial authorization may be approved for 30 days following a therapeutic trial30 days

Initial therapeutic trial of at least 2 weeks required

Re-authorization criteria and length

When continuation criteria are met after initial authorization:

Re-authorization criteria and length: Re-authorization may be approved for another 30-day period contingent on documented objective improvements in the wound30 days

Objective improvements include healthy granulation tissue, progressive contracture, and epithelial spread

Codes Referenced

HCPCS / DME codes (added to policy for interpretation)HCPCS

A9272	Negative pressure wound therapy, disposable, single patient use
A7000	Removed from policy
A7001	Removed from policy

Prior Authorization, Documentation & Billing Guidance

Prior Authorization

Initial therapeutic trial documentation and authorization

Submit medical records documenting that the patient meets initiation criteria and justification for a therapeutic trial of powered NPWT (minimum 2 weeks) and for an initial 30-day authorization. Documentation should show the indication (chronic stage III/IV pressure ulcer >90 days with failed optimal care and/or high-volume drainage; or nonhealing wound ≥30 days with specified comorbidities; or traumatic/surgical wound with failed closure and exposed bone/cartilage/tendon/foreign material).

Affected codes: 97605, 97606
Chronic stage III/IV pressure ulcers >90 days that failed optimal care (high-volume drainage may apply)
Nonhealing wounds ≥30 days despite optimal care with comorbidities (e.g., diabetes, malnutrition, small vessel disease, morbid obesity)
Traumatic/surgical wounds with failed closure and exposed bone/cartilage/tendon/foreign material

Background & Evidence Summary

Background: NPWT uses negative pressure (suction) to aspirate and remove exudate, debris, and infectious material from the wound bed to promote granulation tissue formation and wound healing. The FDA has issued safety alerts (2009 and updated 2011) regarding serious complications, including bleeding and retained dressing pieces, and recommends careful patient selection and frequent monitoring. NPWT systems are FDA-cleared for use in adults but no devices are cleared for infants, children, or adolescents (no NPWT device cleared for those under 18). Powered NPWT should be used as part of a comprehensive wound care program that addresses underlying factors such as diabetes control, nutritional status, and pressure relief.

Evidence label	Summary
Diabetic lower-extremity ulcers evidence	Systematic reviews and RCTs show higher rate of wound healing and fewer amputations with NPWT; studies at risk of bias but evidence sufficient for some benefit.
Single-use NPWT evidence	RCTs (e.g., PICO, SNaP) showed noninferiority for wound area reduction; evidence insufficient to determine overall net health outcome improvement for outpatient single-use devices.
Chronic pressure ulcers evidence	Low-quality RCTs and systematic reviews; insufficient evidence to determine improvement in net health outcome for outpatient NPWT.
Randomized trials and systematic reviews cited	Multiple randomized trials and systematic reviews (e.g., Dumville 2014; Marston 2015; WOLLF 2018; SAWHI 2020 and others through Nov 14, 2025) inform the evidence base.
Guideline citations	Guidelines referenced include AAOS, NICE, AAWC, WHS, IWGDF/IDSA, ACP with varying recommendations regarding NPWT use.

Medicare Determinations

Name	Number	Type	Effective Date
National Coverage	None	NCD

Revision History

06/13/11clarified

Policy updated adding the term 'powered' to existing policy statements and adding that nonpowered NPWT systems are investigational; continuation criteria for powered NPWT clarified.

01/25/12revised

HCPCS code A9272 added to the policy (historical entry).

08/12/25added

New policy 1.01.508 Negative Pressure Wound Therapy (NPWT) Devices in Adults approved August 12, 2025; 90-day provider notification preceded effective date.

Policy Summary

PayerPremera Bluecross

Policy1.01.508 Negative Pressure Wound Therapy (NPWT) Devices in Adults

Policy CodePolicy N/A

Change TypeNew policy; annual review; code clarifications

Effective DateDec 4, 2025

Next Review DateNov 14, 2026

Key ActionSubmit medical records documenting that initiation criteria are met to justify a 2-week therapeutic trial and initial 30-day authorization.

SourceLink

On This Page

Wound that has been nonhealing for at least 30 days despite optimal wound care

Underlying clinical condition(s) known to negatively impact wound healing (one or more)

Examples of underlying conditions

Diabetes
Malnutrition
Malnutrition must be addressed simultaneously with NPWT; documentation must show treatment initiated or planned.
Small vessel disease
Small vessel disease defined as microvascular damage that restricts perfusion and impairs NPWT effectiveness.
Morbid obesity
Morbid obesity defined for this policy as BMI ≥40 kg/m² with poor perfusion and elevated wound complication risk.

Traumatic or surgical wounds with failed closure and exposed structures

Traumatic or surgical wound with failure of immediate or delayed primary closure
Exposed bone, cartilage, tendon, or foreign material within the wound

ALL of the following

Therapeutic trials of powered NPWT systems for the treatment of acute or chronic wounds that do not meet the above initial criteria.
Continuation of powered NPWT when the initial therapeutic trial or subsequent treatment has not resulted in documented objective improvement in the wound.
Continuation of powered NPWT when the wound has developed evidence of complications contraindicating continued NPWT (e.g., necrotic tissue with eschar, untreated osteomyelitis, nonenteric and unexplored fistulae, malignancy in the wound, exposed nerve, exposed anastomotic site, exposed organ).
Continuation of powered NPWT when the wound has healed to the extent that grafting can be performed or the wound can be anticipated to heal completely with other wound care treatments.

Documentation Required

Required documentation for initial 2-week trial

For the initial 2-week powered NPWT trial submit office visit notes with relevant history and physical and clear documentation of why NPWT is required. Include wound staging and duration, evidence of high-volume drainage when applicable, inability to maintain standard dressings due to anatomy, documentation of underlying comorbidities that impair healing, and for malnutrition document that treatment is being addressed simultaneously.

Office visit notes with relevant H&P
Wound stage (III or IV) and duration (>90 days) or nonhealing duration (≥30 days)
Evidence of high-volume drainage when claimed (see threshold 150–200 mL/day)
Documentation of inability to maintain standard dressings due to anatomy
Comorbid conditions (diabetes, malnutrition with concurrent treatment, small vessel disease, morbid obesity)

Documentation Required

Required documentation for continuation

For continuation/re-authorization provide objective wound improvement documented after the initial 2-week trial. Re-authorization is contingent on documented ongoing objective improvements and supports another 30-day period when present.

Affected codes: 97605, 97606
Healthy granulation tissue
Progressive wound contracture with decreasing depth
Commencement of epithelial spread from wound margins

Denial Risk

Noncoverage risk for single-use systems

Claims for single-use (disposable) NPWT systems are considered investigational and may be denied. Do not submit single-use NPWT (disposable) claims expecting standard coverage.

Affected (investigational) codes: 97607, 97608

Documentation Required

Monitoring requirement

Monitor wound healing at least every 14 days while the NPWT system is in use; documentation should reflect this monitoring frequency.

Monitoring frequency: not less than every 14 days

Billing Rule

Approval length and re-authorization

Initial authorization may be approved for 30 days after the therapeutic trial. Re-authorization may be approved for additional 30-day periods only if documented objective wound improvements are present.

Affected codes: 97605, 97606
Initial approval length: 30 days
Re-authorization: additional 30-day periods with documented objective improvement

Documentation Required

Retained documentation requirements (some deleted)

The annual review deleted prior requested documentation fields for wound evaluation location, specific DME, and measurements. Providers should follow the current policy statements and consult the member benefit booklet for coverage specifics.

Deleted documentation requests: wound evaluation location, specific DME, wound measurements
Follow current policy statements and member benefit booklet for required documentation

Billing Rule

HCPCS code updates

HCPCS codes were updated in the policy for interpretation; A9272 was added historically and HCPCS codes A7000 and A7001 were removed from the policy on 04/09/26.

Affected codes: A9272, A7000, A7001
Note: A7000 and A7001 removed from the policy on 04/09/26

12/04/25effective

Policy effective for dates of service on or after December 4, 2025 (new policy 1.01.508).

04/01/26revised

Annual review approved March 9, 2026; literature review updated through November 14, 2025 and references added; deleted documentation section requesting wound evaluation location, specific DME, and measurements; policy statements unchanged.

04/09/26clarifiedLatest

Minor edits to update for clarity to codes in criteria section and minor grammatical edits; codes were added to the policy section for ease of interpretation and application and HCPCS codes A7000 and A7001 were removed (material change).